NCT00517049View on ClinicalTrials.gov

A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

PRO95780

Intravenous repeating dose

DRUG

rituximab

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT00517049 - A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g) | Biotech Hunter | Biotech Hunter